Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME 11:35:08 2024-09-18 EDT 5-day change 1st Jan Change
10.06 EUR -2.00% Intraday chart for Grifols, S.A. +2.57% -34.91%

Cet article est réservé aux membres

Déjà membre ?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading MT
Sector Update: Health Care Stocks Rise Friday Afternoon MT
European Equities Close Higher on Friday; HSBC Mulls Potential Sale of South African Unit MT
Grifols Looking to Hire Shareholder Consultancy Firm Amid Brookfield, Family Takeover Approach MT
Grifols Seeking Consultants to Fend off Shareholder Challenge MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading MT
Grifols Egypt Partners With Orange for Data Center, Communications Infrastructure MT
Grifols Shareholders Tap Spanish Law Group to Ensure Substantial Premium in Brookfield's Offer MT
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower MT
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading MT
Grifols indefinitely postpones October 10 investor day RE
European Equities Traded in the US as American Depositary Receipts Edge Lower Friday; Set to End Week Up 0.5% MT
Brookfield in Talks to Partner With Sovereign Funds For Grifols Offer MT
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid CI
Brookfield in Talks With Sovereign Funds to Join Grifols Acquisition Bid MT
Brookfield in Talks With Sovereign Funds to Join Grifols Acquisition Bid MT
Brookfield in Talks With Sovereign Funds to Join Grifols Acquisition Bid, Bloomberg Reports MT
Biotest Chief Scientific Officer to Step Down MT
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
Chart Grifols, S.A.
More charts
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Employees
23,505
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
10.06EUR
Average target price
17.72EUR
Spread / Average Target
+76.14%
Consensus
  1. Stock Market
  2. Equities
  3. GRF Stock
  4. News Grifols, S.A.
  5. Grifols Receives Takeover Interest from Founding Family, Brookfield; Shares Suspended
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW